Cell Source Stock Return On Equity
| CLCS Stock | USD 0.40 0.06 13.04% |
Fundamental analysis of Cell Source allows traders to better anticipate movements in Cell Source's stock price by examining its financial health and performance throughout various phases of its business cycle.
Cell |
Cell Source Company Return On Equity Analysis
Cell Source's Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Based on the latest financial disclosure, Cell Source has a Return On Equity of 0.0. This is 100.0% lower than that of the Healthcare sector and 100.0% lower than that of the Biotechnology industry. The return on equity for all United States stocks is 100.0% lower than that of the firm.
Cell Return On Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Cell Source's direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Cell Source could also be used in its relative valuation, which is a method of valuing Cell Source by comparing valuation metrics of similar companies.Cell Source is currently under evaluation in return on equity category among its peers.
Cell Fundamentals
| Return On Asset | -3.78 | |||
| Current Valuation | 59.65 M | |||
| Shares Outstanding | 35.25 M | |||
| Shares Owned By Insiders | 32.13 % | |||
| Price To Earning | (3.28) X | |||
| EBITDA | (4.11 M) | |||
| Net Income | (5.47 M) | |||
| Cash And Equivalents | 93.09 K | |||
| Total Debt | 6.5 M | |||
| Debt To Equity | (1.04) % | |||
| Current Ratio | 0.03 X | |||
| Book Value Per Share | (0.34) X | |||
| Cash Flow From Operations | (3.38 M) | |||
| Earnings Per Share | (0.20) X | |||
| Beta | -64.41 | |||
| Market Capitalization | 10.61 M | |||
| Total Asset | 313.77 K | |||
| Retained Earnings | (21.7 M) | |||
| Working Capital | (7.79 M) | |||
| Current Asset | 213.56 K | |||
| Current Liabilities | 8 M | |||
| Net Asset | 313.77 K |
About Cell Source Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Cell Source's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cell Source using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cell Source based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Cell Pink Sheet Analysis
When running Cell Source's price analysis, check to measure Cell Source's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cell Source is operating at the current time. Most of Cell Source's value examination focuses on studying past and present price action to predict the probability of Cell Source's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cell Source's price. Additionally, you may evaluate how the addition of Cell Source to your portfolios can decrease your overall portfolio volatility.